{"filing":{"accession_number":"0001819790-26-000063","cik":"0001819790","ticker":"TARS","company_name":"Tarsus Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"tars-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/tars-20260806.htm"},"events":[{"id":25982,"run_id":23594,"accession_number":"0001819790-26-000063","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Tarsus Pharmaceuticals issued a press release on August 6, 2026, disclosing financial results for the second quarter and six months ended June 30, 2026. The filing explicitly states under Item 2.02 that the company \"issued a press release, which, among other matters, sets forth the Company's results of operations for the three and six months ended June 30, 2026.\" The press release includes detailed quarterly and year-to-date financial metrics (product sales of $173.9M in Q2 2026 vs. $102.7M in Q2 2025, net loss of $18.6M vs. $20.3M, and updated full-year guidance of $685-705M), making this a standard earnings release disclosure.","company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26944,"accession_number":"0001819790-26-000063","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Tarsus Pharmaceuticals issued a press release on August 6, 2026, disclosing financial results for the second quarter and six months ended June 30, 2026. The filing explicitly states under Item 2.02 that the company \"issued a press release, which, among other matters, sets forth the Company's results of operations for the three and six months ended June 30, 2026.\" The press release includes detailed quarterly and year-to-date financial metrics (product sales of $173.9M in Q2 2026 vs. $102.7M in Q2 2025, net loss of $18.6M vs. $20.3M, and updated full-year guidance of $685-705M), making this a standard earnings release disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:52:20.415079+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26944,"accession_number":"0001819790-26-000063","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Tarsus Pharmaceuticals issued a press release on August 6, 2026, disclosing financial results for the second quarter and six months ended June 30, 2026. The filing explicitly states under Item 2.02 that the company \"issued a press release, which, among other matters, sets forth the Company's results of operations for the three and six months ended June 30, 2026.\" The press release includes detailed quarterly and year-to-date financial metrics (product sales of $173.9M in Q2 2026 vs. $102.7M in Q2 2025, net loss of $18.6M vs. $20.3M, and updated full-year guidance of $685-705M), making this a standard earnings release disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:52:20.415079+00:00","company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","filing_date":"2026-08-06"}]}